U.S. FDA delays approval of GSK bird flu vaccine
LONDON, March 25
LONDON, March 25 (Reuters) - U.S. regulators have delayed approval of an H5N1 bird flu vaccine from GlaxoSmithKline , designed to be used in a pandemic.
The vaccine had been backed by an expert panel in November but GSK said on Monday the Food and Drug Administration (FDA) had informed it that additional review time was needed before approval.
Britain's biggest drugmaker said the delay was "due to an administrative matter that has recently been rectified", adding the company and the FDA were working to complete to review in a timely manner.
- Man called Bitcoin's father denies ties, leads LA car chase
- Ukraine standoff intensifies, Russia says sanctions will 'boomerang' |
- Florida mayor fights backyard gun ranges in 'Gunshine State'
- Apple loses bid for U.S. ban on Samsung smartphone sales
- 'Everything is fine', Pistorius told guard after shooting girlfriend |